arrow
B

Brian M. Slomovitz

Mount Sinai Medical Center
H指数:45
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pathologic response and molecular correlates of giredestrant in patients with grade 1 clinical stage IA endometrioid endometrial cancer: the phase II endomERA study

Giredestrant在G1期临床IA期子宫内膜样子宫内膜癌患者中的病理反应及分子相关性:endomERA II期研究

2026-10-130
OA
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy

聚腺苷二磷酸核糖聚合酶抑制剂尼拉帕利维持治疗接受多斯塔利姆单抗联合化疗的原发进展或复发性子宫内膜癌患者

2026-06-060
PRE
Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial

Tisotumab vedotin在日本复发性或转移性宫颈癌患者中的应用:来自innovaTV 301/ENGOT-cx12/GOG-3057试验的结果

2025-12-310
PRE
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: 1-Year Follow-Up After Final Analysis of the ENGOT-en9/LEAP-001 Phase 3 Trial

一线仑伐替尼联合帕博利珠单抗与化疗治疗晚期子宫内膜癌:ENGOT-en9/LEAP-001 III期试验最终分析后的1年随访

2025-11-110
PRE
A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel

一份关于接受多塔利单抗联合卡铂-紫杉醇治疗子宫内膜癌患者生存情况的通俗语言摘要出版物

2025-10-090
OA
The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution

GOG基金会和EVA/LACOG合作伙伴关系:一个用于临床 trial 执行的协作战略联盟

2025-06-270
PRE
Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment

重新利用美国食品药品监督管理局批准的癌症疗法:探索低级别浆液性卵巢癌治疗中的内分泌和靶向通路

2025-05-150
PRE
Approach to radical hysterectomy for cervical cancer after the Laparoscopic Approach to Cervical Cancer trial and associated complications: a National Surgical Quality Improvement Program study

腹腔镜子宫颈癌手术后的宫颈癌根治性子宫切除术及并发症:一项全国外科质量改进计划研究

2025-02-013
PRE
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab With/Without Olaparib In Endometrial Cancer: Exploratory Analyses Of Histology, Biomarker Heterogeneity And Efficacy In The DUO-E Mismatch Repair Proficient Subpopulation

Durvalumab联合卡铂/紫杉醇后序贯Durvalumab联合或不联合奥拉帕利在子宫内膜癌中的探索性分析:DUO-E研究错配修复 proficient 亚人群的组织学、生物标志物异质性和疗效分析

2025-02-010
PRE